Associated Genetic Biomarkers
NCI Definition: The most common histologic type of breast carcinoma. Representative examples include invasive ductal carcinoma not otherwise specified, ductal carcinoma in situ, inflammatory carcinoma, secretory carcinoma, signet ring cell carcinoma, tubular carcinoma, invasive lobular carcinoma, and lobular carcinoma in situ. 
Breast adenocarcinomas most frequently harbor alterations in PIK3CA, TP53, CDH1, RYR2, and USH2A .
PIK3CA Mutation (somatic), PIK3CA Mutation, TP53 Mutation, PIK3CA H1047R, and CDH1 Mutation are the most common alterations in breast adenocarcinoma .
There are 20 clinical trials for breast adenocarcinoma, of which 19 are open and 1 is completed or closed. Of the trials that contain breast adenocarcinoma as an inclusion criterion, 7 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 6 are phase 3 (5 open), and 2 are no phase specified (2 open).
ERBB2 is the most frequent gene inclusion criterion for breast adenocarcinoma clinical trials .
Palbociclib, sar439859, and carboplatin are the most common interventions in breast adenocarcinoma clinical trials.
Significant Genes in Breast Adenocarcinoma
ERBB2 is mutated in 9.74% of breast adenocarcinoma patients .
ERBB2 is an inclusion eligibility criterion in 17 clinical trials for breast adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain ERBB2 status and breast adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 5 are phase 3 (4 open), and 2 are no phase specified (2 open) .
Palbociclib, surgery, and sar439859 are the most frequent therapies in breast adenocarcinoma trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.